实用老年医学

实用老年医学 ›› 2025, Vol. 39 ›› Issue (3): 325-330.doi: 10.3969/j.issn.1003-9198.2025.03.026

• 专家共识 • 上一篇    

恩他卡朋双多巴在早期帕金森病的临床应用专家指导意见

恩他卡朋双多巴在早期帕金森病的临床应用专家指导意见编写组(陈玲, 承欧梅, 崔桂云, 黄卫, 刘春风, 刘卫国, 刘振国, 毛成洁, 毛薇, 吴云成, 朱晓冬, 郑慧芬, 程筱雨)   

  1. 510080 广东省广州市,中山大学附属第一医院(陈玲);400016 重庆市,重庆医科大学第一附属医院(承欧梅);221006 江苏省徐州市,徐州医科大学附属医院(崔桂云);330006 江西省南昌市,南昌大学第二附属医院(黄卫);215004 江苏省苏州市,苏州大学附属第二医院(刘春风,毛成洁,程筱雨);210029 江苏省南京市,南京脑科医院(刘卫国);200092 上海市,上海交通大学医学院附属新华医院(刘振国);100053 北京市,首都医科大学宣武医院(毛薇);200080 上海市,上海交通大学医学院附属第一人民医院(吴云成);300052 天津市,天津医科大学总医院(朱晓冬);210024 江苏省南京市,南京医科大学附属老年医院(郑慧芬)
  • 出版日期:2025-03-20 发布日期:2025-04-03
  • 通讯作者: 刘春风,Email:liuchunfeng@suda.edu.cn

Expert Advice on the Clinical Application of Levodopa/Carbidopa/Entacapone at Early Stage of Parkinson's Disease

Expert Guidance Writing Group for the Levodopa/Carbidopa/Entacapone in Early Parkinson's Diseas (CHEN Ling, CHENG Oumei, CUI Guiyun, HUANG Wei, LIU Chunfeng, LIU Weiguo, LIU Zhenguo, MAO Chengjie, MAO Wei, WU Yuncheng, ZHU Xiaodong, ZHENG Huifen, CHENG Xiaoyu)   

  1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China (CHEN Ling); The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China (CHENG Oumei); The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China (CUI Guiyun); The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China (HUANG Wei); The Second Affiliated Hospital of Soochow University, Suzhou 215004, China (LIU Chunfeng, MAO Chengjie, CHENG Xiaoyu); Nanjing Brain Hospital, Nanjing 210029, China (LIU Weiguo); Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China (LIU Zhenguo); Xuanwu Hospital Capital Medical University, Beijing 230012, China (MAO Wei); Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 210080, China (WU Yuncheng); General Hospital of Tianjin Medical University, Tianjin 300052, China (ZHU Xiaodong); The Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing 210024, China (ZHENG Huifen)
  • Online:2025-03-20 Published:2025-04-03
  • Contact: LIU Chunfeng, Email: liuchunfeng@suda.edu.cn

PDF (PC)

41

摘要： 帕金森病早期是改善症状并延缓疾病进展的关键时期,恩他卡朋双多巴是指南推荐的帕金森病早期治疗药物之一。为了更好地规范和指导恩他卡朋双多巴在早期帕金森病的应用,编写组深入分析了国内外循证医学证据,结合我国临床实践具体情况,共同讨论、制订了本专家指导意见,内容涵盖恩他卡朋双多巴对传统复方左旋多巴药代动力学的优化作用,对早期帕金森病患者病人的有效性和安全性,适用人群,用药方案,常见不良反应的处理以及治疗依从性等,以期为临床规范和合理用药提供参考。

关键词: 帕金森病, 早期, 恩他卡朋, 恩他卡朋双多巴, COMT抑制剂, 指导意见

Abstract: The early stage of Parkinson’s disease is a key period to improve symptoms and delay the disease progression. Levodopa/Carbidopa/Entacapone is one of the recommended drugs for the treatment of early Parkinson’s disease in the guidelines. To better standardize and guide the application of levodopa/carbidopa/entacapone in early Parkinson’s disease, the writing group has conducted a thorough analysis of both domestic and international evidence-based medicine, taking into account of the specific circumstances of clinical practice in China, and jointly discussed and formulated this expert advice. The content encompasses the optimization effects of levodopa/carbidopa/entacapone on the pharmacokinetics of traditional compound levodopa, the efficacy and safety of these medications for patients with early Parkinson’s disease, the target population, dosing regimens, management of common adverse reactions and treatment adherence, aiming to provide references for clinical standardization and rational drug use.

Key words: Parkinson's disease, early stage, entacapone, levodopa/carbidopa/entacapone, COMT inhibitors, advice

中图分类号: